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Background: Compared to aspirin, apixaban reduces stroke risk in patients unsuitable for warfarin therapy by 63% without significantly increasing 
the risk of major bleeding. The objective of this model was to estimate the costs, quality-adjusted life-years (QALYs), and incremental cost-
effectiveness of apixaban compared to aspirin in patients with atrial fibrillation (AF).
Methods: On the basis of the results from Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are 
Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial and other published studies, we constructed a Markov model to evaluate the costs 
(in 2011 US$), QALYs, and the incremental cost-effectiveness of apixaban 5 mg twice daily compared to aspirin 81-324 mg daily from the Medicare 
perspective. We assumed a hypothetical cohort of 65-year-old AF patients with a CHADS2 score of 2 and a low risk of bleeding. We utilized a one 
month cycle length, a time horizon of 35 years, and a discount rate of 3% per annum. One-way and probabilistic sensitivity analyses (PSA) were 
performed.
Results: The base-case analysis revealed the total costs per patient were $92,087 and $109,654 for apixaban and aspirin, respectively. 
Corresponding QALYs were 9.94 and 8.86 for apixaban and aspirin, making apixaban a dominant economic strategy. One-way sensitivity analyses 
showed that results were sensitive to changes in the baseline rates of stroke on aspirin and the monthly cost of moderate to severe stroke. PSA 
revealed that apixaban dominated aspirin in 93% of 10,000 iterations, and was cost-effective in 99% at a willingness-to-pay threshold of $50,000 
per QALY.
Conclusions: In AF patients aged 65 years or older with a CHADS2 score of 2 and a low risk of bleeding who are unsuitable for warfarin therapy, 
apixaban is likely an economically dominant alternative to aspirin.
